Eagle Pharmaceuticals, Inc. (EGRX)
Largest Insider Buys in Sector
EGRX Stock Price History Chart
EGRX Stock Performance
About Eagle Pharmaceuticals, Inc.
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Insider Activity of Eagle Pharmaceuticals, Inc.
Over the last 12 months, insiders at Eagle Pharmaceuticals, Inc. have bought $0 and sold $599,336 worth of Eagle Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Eagle Pharmaceuticals, Inc. have bought $0 and sold $2.31M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 350 shares for transaction amount of $19,406 was made by Meyers Pete A. (Chief Financial Officer) on 2017‑08‑16.
List of Insider Buy and Sell Transactions, Eagle Pharmaceuticals, Inc.
| 2023-11-02 | Sale | Tarriff Scott | CEO | 10,694 0.0805% | $13.87 | $148,326 | -64.02% | |
| 2023-11-01 | Sale | Tarriff Scott | CEO | 10,925 0.0836% | $13.82 | $150,984 | -63.53% | |
| 2023-10-03 | Sale | Tarriff Scott | CEO | 10,734 0.0786% | $14.46 | $155,174 | -63.34% | |
| 2023-10-02 | Sale | Tarriff Scott | CEO | 9,511 0.0733% | $15.23 | $144,853 | -65.55% | |
| 2023-05-16 | Sale | Tarriff Scott | CEO | 15,000 0.1151% | $19.98 | $299,700 | -55.02% | |
| 2023-05-15 | Sale | Tarriff Scott | CEO | 15,000 0.1151% | $21.07 | $315,992 | -57.19% | |
| 2023-05-12 | Sale | Tarriff Scott | CEO | 15,000 0.1131% | $20.27 | $304,014 | -54.20% | |
| 2023-05-11 | Sale | Tarriff Scott | CEO | 15,000 0.1135% | $20.71 | $310,650 | -54.64% | |
| 2022-09-06 | Sale | Edlin Richard A. | 6,800 0.0512% | $30.99 | $210,732 | -10.69% | ||
| 2019-10-25 | Sale | Hudson Executive Capital LP | director | 15,437 0.1119% | $63.57 | $981,302 | -23.33% | |
| 2019-10-24 | Sale | Hudson Executive Capital LP | director | 1,494 0.0109% | $62.53 | $93,413 | -21.42% | |
| 2019-10-23 | Sale | Hudson Executive Capital LP | director | 200 0.0015% | $62.58 | $12,516 | -21.06% | |
| 2019-10-22 | Sale | Hudson Executive Capital LP | director | 6,567 0.048% | $62.68 | $411,618 | -21.14% | |
| 2019-10-21 | Sale | Hudson Executive Capital LP | director | 3,849 0.0281% | $62.56 | $240,791 | -20.90% | |
| 2019-10-18 | Sale | Hudson Executive Capital LP | director | 1,600 0.0118% | $62.61 | $100,174 | -19.82% | |
| 2019-10-17 | Sale | Hudson Executive Capital LP | director | 13,842 0.1007% | $62.58 | $866,196 | -20.80% | |
| 2019-10-16 | Sale | Hudson Executive Capital LP | director | 102 0.0007% | $62.50 | $6,375 | -19.97% | |
| 2019-10-15 | Sale | Hudson Executive Capital LP | director | 3,909 0.0287% | $62.63 | $244,836 | -19.71% | |
| 2019-10-11 | Sale | Hudson Executive Capital LP | director | 16,300 0.1192% | $60.39 | $984,419 | -16.19% | |
| 2019-10-10 | Sale | Hudson Executive Capital LP | director | 7,829 0.0569% | $60.16 | $471,002 | -16.16% |
Insider Historical Profitability
| Tarriff Scott | CEO | 545447 4.1999% | $4.92 | 0 | 24 | |
| Moorin Jay | 4770828 36.7354% | $4.92 | 1 | 0 | <0.0001% | |
| SCHREIBER ALAIN | 4770828 36.7354% | $4.92 | 1 | 0 | <0.0001% | |
| ProQuest Associates IV LLC | 10 percent owner | 4770828 36.7354% | $4.92 | 1 | 0 | <0.0001% |
| Braunstein Douglas L | director | 811777 6.2507% | $4.92 | 1 | 2 | +18.31% |
| Hudson Executive Capital LP | director | 732777 5.6424% | $4.92 | 0 | 16 | |
| ProQuest Management LLC | 10 percent owner | 41081 0.3163% | $4.92 | 0 | 2 | |
| Edlin Richard A. | 22600 0.174% | $4.92 | 1 | 1 | <0.0001% | |
| RATOFF STEVEN B | director | 13324 0.1026% | $4.92 | 1 | 2 | <0.0001% |
| FLAUM SANDER A | director | 11374 0.0876% | $4.92 | 0 | 4 | |
| ProQuest Investments IV, L.P. | 10 percent owner | 6777 0.0522% | $4.92 | 0 | 30 | |
| Graves Michael | director | 1000 0.0077% | $4.92 | 1 | 0 | +10.2% |
| Pernock David | Pres. & Chief Comm. Officer | 966 0.0074% | $4.92 | 4 | 0 | <0.0001% |
| Meyers Pete A. | Chief Financial Officer | 700 0.0054% | $4.92 | 2 | 0 | <0.0001% |
| Krill Steven L. | EVP & Chief Scientific Officer | 0 0% | $4.92 | 0 | 12 |
Institutional Investor Ownership
| Nantahala Capital Management Llc | $6.6M | 9.69 | 1.26M | New | +$6.6M | 0.68 | |
| Aigh Capital Management Llc | $6.22M | 9.14 | 1.19M | New | +$6.22M | 3.69 | |
| BlackRock | $4.7M | 6.91 | 897,806 | -8.84% | -$456,414.63 | <0.0001 | |
| AQR Capital | $4.61M | 6.77 | 879,073 | +78.07% | +$2.02M | 0.01 | |
| The Vanguard Group | $3.36M | 4.93 | 640,754 | +0.41% | +$13,781.20 | <0.0001 | |
| Morgan Stanley | $1.97M | 2.89 | 375,329 | +26.43% | +$411,156.61 | <0.0001 | |
| LSV Asset Management | $1.75M | 2.57 | 334,158 | -14.7% | -$301,826.08 | <0.01 | |
| Renaissance Technologies | $1.75M | 2.57 | 333,850 | +13.38% | +$206,411.86 | <0.01 | |
| Bank of America | $1.71M | 2.51 | 325,504 | +74.11% | +$725,980.63 | <0.0001 | |
| J. Goldman & Company | $1.36M | 1.99 | 258,696 | +4.98% | +$64,300.04 | 0.06 | |
| Millennium Management LLC | $1.35M | 1.99 | 257,864 | -50.64% | -$1.39M | <0.01 | |
| Marshall Wace | $1.35M | 1.98 | 257,469 | +79.01% | +$595,488.63 | <0.01 | |
| Two Sigma Advisers LP | $1.24M | 1.82 | 236,317 | +6.44% | +$74,931.99 | <0.01 | |
| Geode Capital Management | $1.21M | 1.78 | 231,641 | +2.82% | +$33,256.85 | <0.0001 | |
| D. E. Shaw & Co. | $1.15M | 1.69 | 219,811 | +34.45% | +$295,122.13 | <0.01 | |
| State Street | $1.12M | 1.65 | 213,667 | -4.01% | -$46,777.48 | <0.0001 | |
| Los Angeles Capital Management LLC | $1M | 1.48 | 191,732 | +110.09% | +$526,462.97 | <0.01 | |
| Assenagon Asset Management S.A. | $971,166.00 | 1.43 | 185,337 | -14.85% | -$169,414.46 | <0.01 | |
| Goldman Sachs | $931,709.00 | 1.37 | 177,807 | -8.26% | -$83,929.11 | <0.0001 | |
| Dimensional Fund Advisors | $896,518.00 | 1.32 | 171,091 | -30.59% | -$395,127.95 | <0.0001 | |
| Two Sigma | $856,399.00 | 1.26 | 163,435 | -21.28% | -$231,497.85 | <0.01 | |
| American Century Investments | $644,530.00 | 0.95 | 123,002 | +10.66% | +$62,114.91 | <0.0001 | |
| Tang Capital Management, LLC | $622,811.00 | 0.92 | 118,857 | 0% | +$0 | <0.01 | |
| Invesco | $614,401.00 | 0.9 | 117,252 | +599.39% | +$526,552.33 | <0.0001 | |
| Man Group Plc | $551,358.00 | 0.81 | 105,221 | +70.97% | +$228,867.46 | <0.01 | |
| Northern Trust | $521,391.00 | 0.77 | 99,502 | -6.11% | -$33,908.07 | <0.0001 | |
| Trexquant Investment LP | $468,676.00 | 0.69 | 89,442 | -29.17% | -$193,041.57 | 0.01 | |
| Charles Schwab | $387,377.00 | 0.57 | 73,927 | +2.28% | +$8,619.79 | <0.0001 | |
| Dgs Capital Management Llc | $324,587.00 | 0.48 | 61,944 | +442.46% | +$264,751.36 | 0.09 | |
| JPMorgan Chase | $307,226.00 | 0.45 | 58,631 | -4.77% | -$15,384.62 | <0.0001 | |
| Kennedy Capital Management Inc | $292,120.00 | 0.43 | 55,748 | -24.47% | -$94,639.80 | 0.01 | |
| Acadian Asset Management | $274,000.00 | 0.4 | 52,446 | -81.76% | -$1.23M | <0.01 | |
| Deutsche Bank | $255,712.00 | 0.38 | 48,800 | 0% | +$0 | <0.0001 | |
| Citadel Advisors LLC | $229,140.00 | 0.34 | 43,729 | -39.18% | -$147,610.83 | <0.0001 | |
| Nuveen | $220,698.00 | 0.32 | 42,118 | -75.63% | -$685,029.45 | <0.0001 | |
| BNY Mellon | $184,904.00 | 0.27 | 35,287 | -15.65% | -$34,311.54 | <0.0001 | |
| Bridgeway Capital Management | $167,156.00 | 0.25 | 31,900 | 0% | +$0 | <0.01 | |
| Royal Bank of Canada | $147,000.00 | 0.22 | 28,156 | +691.79% | +$128,434.44 | <0.0001 | |
| PDT Partners | $141,784.00 | 0.21 | 27,058 | New | +$141,784.00 | 0.01 | |
| Denali Advisors | $139,384.00 | 0.21 | 26,600 | 0% | +$0 | 0.04 | |
| Bank of Montreal | $137,206.00 | 0.2 | 25,694 | New | +$137,206.00 | <0.0001 | |
| Barclays | $119,000.00 | 0.17 | 22,590 | -23.64% | -$36,837.85 | <0.0001 | |
| Fidelity Investments | $115,820.00 | 0.17 | 22,103 | +6.69% | +$7,262.66 | <0.0001 | |
| State Of Wyoming | $113,441.00 | 0.17 | 21,649 | New | +$113,441.00 | 0.01 | |
| AllianceBernstein | $112,084.00 | 0.17 | 21,390 | 0% | +$0 | <0.0001 | |
| Jump Financial Llc | $107,541.00 | 0.16 | 20,523 | -47.24% | -$96,295.91 | <0.01 | |
| Occudo Quantitative Strategies Lp | $101,515.00 | 0.15 | 19,373 | -57.62% | -$138,037.97 | 0.02 | |
| RhumbLine Advisers | $89,940.00 | 0.13 | 17,166 | -1.01% | -$916.90 | <0.0001 | |
| Savant Capital Management | $87,267.00 | 0.13 | 16,654 | New | +$87,267.00 | <0.01 | |
| T. Rowe Price | $83,000.00 | 0.12 | 15,748 | New | +$83,000.00 | <0.0001 |